🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This week we presented new data reinforcing the clinical benefit of our medicine for #IgAN and a late-breaking presentation in #FSGS at ASN #KidneyWk. Press release: ir.travere.com/news-releases/…

We’d like to extend a huge thank you to American Society of Nephrology and to everyone who joined us at #ASN24 #KidneyWk. It was a pleasure coming together and sharing our clinical data and research in #IgAN and #FSGS. Thank you to all those who contributed to another thought-provoking and inspiring

Today we reported our third quarter 2024 financial results. Press release: bit.ly/3Al4n3U

On Sunday, December 8 at 8 a.m. PT, GlomCon is hosting a seminar about targeting glomerular injury to preserve kidney function in patients with #IgAnephropathy. Dr. Dia Waguespack will moderate a panel with Drs. Swati Arora and Dana Rizk, following a presentation by Dr. Chris

Our president and CEO, Eric Dube, Ph.D., will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT. Press release: bit.ly/40kjnJs #JPMorgan2025 #TravereTherapeutics #InRareForLife

Today we provided a corporate update and outlook for 2025. Press release: bit.ly/406c86I

We are delighted to share 2 presentations at #ISNWCN #WCN2025 on our research in #RareKidneyDisease, including on the effect of sparsentan as a first-line treatment in patients with #IgAnephropathy, and on the implications of proteinuria remission in #IgAN on eGFR. At Travere, we

Today we announced that we plan to submit a supplemental New Drug Application (sNDA) to the U.S. FDA for sparsentan in focal segmental glomerulosclerosis (#FSGS). Press release: bit.ly/4gDGTGq #InRareForLife

Today we reported our fourth quarter and full year 2024 financial results and provided a corporate update. Press Release: bit.ly/4i8pWoB

Tune in for a new episode of the #RareKidneyDisease Show, a podcast that is part of the RKD Scientific Network as Drs. Lerma, Cheung, Heerspink, and Hendry discuss key data presented at #KidneyWk 2024 bit.ly/439qVAK

Today we announced that we have submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). Press release: bit.ly/3FMfqFx

At ACMG #ACMGMtg25 this week in Los Angeles, we will share results from the ACAPELLA Study, our natural history study in classical HCU to gain greater understanding of disease progression in this challenging metabolic condition. #InRareForLife

Did you miss our medical affairs-sponsored webinar with Int Society of Nephrology on the evolving #IgAN therapeutic landscape? Click to catch up on “A New Dawn for IgA Nephropathy – Redefining What is Possible with Sparsentan.” Discover more on the Travere ISN Webinar page:

Today we announced that we will present new data at the National Kidney Foundation Spring Clinical Meetings 2025. #InRareForLife bit.ly/41UsdP5

We are delighted to share 3 presentations at the National Kidney Foundation #SCM25 this week on our research in #RareKidneyDisease, including #FSGS and #IgAN. Check out all our presentations at the Spring Clinical Meetings. At Travere, we are #InRareForLife. #NKF2025

We were honored to join leading experts in nephrology at the National Kidney Foundation Spring Clinical Meetings #SCM25 as we shared research shaping the future of #RareKidneyDisease. Thank you to the National Kidney Foundation and all the presenters for fostering such a collaborative and impactful

Today we announced with CSL Vifor standard EU approval of FILSPARI® (sparsentan) for IgA nephropathy. #InRareForLife Press release: bit.ly/3GvaHIU

Today we reported our first quarter earnings and provided a corporate update. Press Release: bit.ly/3YoOanb

We are delighted to be in Portland for the ANNA National Symposium. We have 2 posters we’re presenting here, one on the implications of proteinuria remission on the eGFR trajectory in patients with #IgAnephropathy (IgAN) in the Phase 3 PROTECT Study. Our other poster

Today we announced that the FDA has accepted our sNDA for FILSPARI® (sparsentan) in FSGS. bit.ly/3GXTxUr